ดูไบ, สหรัฐอาหรับเอมิเรตส์, April 30, 2024 (GLOBE NEWSWIRE) — One Za’abeel การพัฒนาแบบผสมผสานอันเป็นเอกลักษณ์ที่พัฒนาโดย ICD (Investment Corporation of Dubai) มีความยินดีที่จะประกาศเปิดตัว The Offices ซึ่งเป็นพื้นที่สำนักงานสุดหรูของบริษัทที่ได้รับใบอนุญาตสองแบบภายในอาคาร One Za’abeel Tower สำนักงานเกรด A ที่จะกลายเป็นที่อยู่ของสถานประกอบการทางธุรกิจระดับสูงสุดของดูไบ โดยจะดึงดูดองค์กรระดับโลกและองค์กรระดับท้องถิ่นด้วยใบอนุญาตสองแบบอันเป็นเอกลักษณ์สำหรับทั้งบริษัทที่จดทะเบียนภายใต้ Dubai World Trade Center Free Zone (DWTC FZ) และบริษัทที่จดทะเบียนภายใต้แผ่นดินใหญ่
One Za’abeel ประกอบด้วยตึกระฟ้า 2 หลัง ได้แก่ One Za’abeel Tower และ One Za’abeel The Residences เชื่อมต่อกันด้วย The Link ซึ่งเป็นอาคารยาว 230 เมตรที่มีลักษณะเหมือนคานแขวนอยู่เหนือพื้นดิน 100 เมตร รูปแบบที่เป็นเอกลักษณ์ของการพัฒนาแบบผสมผสาน ควบคู่ไปกับทำเลที่ตั้งเชิงกลยุทธ์ จึงได้รับฉายาว่า “ประตูสู่ย่านศูนย์กลางธุรกิจของดูไบ”
ทำเลที่ดีเยี่ยมของ The Offices พร้อมด้วยการพัฒนาแบบผสมผสานช่วยให้สามารถเข้าถึงข้อเสนอทั้งหมดของ One Za’abeel ได้อย่างง่ายดาย ผู้เช่าสามารถเชิญแขกมารับประทานอาหารในร้านอาหารระดับดาวมิชลินหลายแห่งใน The Link จัดการประชุมหรืออีเวนต์ในสถานที่จัดการประชุมภายในรีสอร์ต One&Only One Za’abeel เชิญแขกมาพักที่รีสอร์ต หรือมาออกกำลังกายที่ฟิตเนสและพักผ่อนหย่อนใจที่โรงแรม SIRO หรือเพียงแค่มาเยี่ยมชมร้านค้าต่าง ๆ และเลือกซื้ออาหารและเครื่องดื่มในพื้นที่ค้าปลีก
LUXEMBOURG / ACCESSWIRE / April 30, 2024 / Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a Molecular Farming food-ingredient company, announced today the granting of a patent family in the United States for its SPC2 product produced in safflower with Molecular Farming technology. This new patent adjudication will give the company, through its U.S. sole-owned subsidiary AG Biomolecules LLC, exclusivity for the use of the technology until 2041. Find the link to the patent here: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11965169.
Moolec Science Logo
Moolec, whose technological platform has been under development for more than a decade, is known for pioneering the production of a bovine protein in a crop for the food industry. With the development and commercialization of the world’s first product for the food industry using Molecular Farming, Moolec shattered barriers and revealed the potential of this groundbreaking technology in the industrial biotech sector. This milestone transcended the limitations of traditional biotech practices, opening doors to innovation previously confined to pharmaceuticals.
The recently patented technology encompasses safflower plants, inclusive of their seeds, engineered with specific DNA sequences (transgenic event) aimed at improving the expression of bovine chymosin in safflower seeds.
Amit Dhingra, Moolec Science’s Chief Science Officer, emphasized, "This new family of patents not only ensures intellectual property protection for our product but also represents a platform for additional opportunities for Moolec’s safflower platform." He then finished by saying, "It positions us to produce new proteins and products, leveraging the unique attributes of this crop. Moolec remains committed to innovative advancements in sustainable biotechnology, driving impactful change across food industries."
Additionally, the patent extends to cover the DNA vectors utilized for transforming the safflower plant and the DNA sequences required for detecting the transgenic event.
While the patent has been successfully secured in the United States, a parallel application has been submitted in Argentina, a crucial strategic territory for Moolec’s safflower technology initiatives. Although the Argentinian patent application is currently pending, the patent family boasts a lifespan extending until 2041.
About Moolec Science SA
Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company’s mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins, for good and for all. Moolec’s technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company’s Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.
Forward-Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.
HEIDELBERG, GERMANY / ACCESSWIRE / April 30, 2024 / BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to overcome the immunosuppressive microenvironment of solid tumors.
Independent of tumor indication, the general immunogenicity of a tumor is positively correlated with a better prognosis and a more robust response to immune checkpoint blockade. The current paradigm envisions tumor mutations as one of the sources of immunogenic neoantigens, which are expressed and presented on the surface of the tumor cells and recognized by the immune system to mount an effective anti-tumor response. The main objective of this research group is to identify how the DNA damage response (DDR) can be harnessed to increase the immunogenicity of tumor cells. The final goal is to design novel therapeutic approaches that promote a favorable tumor microenvironment for immunotherapies.
Dr. Semih Akincilar, the scientist leading this project, explains: "Using colorectal cancer as a model, we will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. This will help us to better understand the links between DNA damage response and tumor immunogenicity, with significant implications for oncological treatment."
The BioMed X Institute and Merck have been collaborating since 2013, partnering on both oncology and immunology research projects, with the end goal of developing new therapies for cancer and autoimmune diseases. "With our most recent projects in collaboration with Merck and others, we are deepening our expertise in tumor immunology," said Christian Tidona, Founder and Managing Director of the BioMed X Institute. Further details about this project can be found on the BioMed X Institute website (www.bio.mx).
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
SEOUL, Global credit appraiser SandP Global Ratings said Tuesday it has maintained its credit rating on South Korea at “AA,” with a stable outlook.
SandP has kept South Korea’s long-term sovereign credit rating at the third-highest level on the company’s table since August 2016, when it upgraded the rating by one notch from “AA-.”
“The stable rating outlook reflects our expectation that (South) Korea will maintain average growth rates that are higher than most other high-income economies for at least the next three to five years,” the agency said in a report.
SandP expected the South Korean economy to grow 2.2 percent this year, accelerating from last year’s 1.4 percent gain.
“Over the next three years, real gross domestic product (GDP) growth should be sustained at levels close to or above 2 percent annually,” the agency said, adding that both exports and domestic demand “should strengthen from last year.”
The forecast was on a par with the growth outlook by the South Korean government and the Organiza
tion for Economic Cooperation and Development.
The Bank of Korea forecast 2.1 percent growth, and the International Monetary Fund presented a 2.3 percent expansion.
Exports, a key economic growth engine for South Korea, rose for the sixth consecutive month in March after a yearlong downturn, driven by solid global demand for semiconductors.
The agency also forecast that inflation would narrow to 2.6 percent for 2024 from last year’s 3.6 percent, which “should allow interest rates to decline from levels in 2023.”
Retail prices have been trending down, but inflationary pressure has eased at a slower-than-expected pace due to the high prices of fruit, farm produce and energy.
As for public finances, the agency expected the government deficit could rebound to 1 percent of GDP this year due mainly to weaker revenue collection stemming from relatively weak economic growth last year.
“Geopolitical risks continue to weigh on the sovereign ratings on South Korea. However, we do not believe that recent developmen
ts in the Democratic Republic of Korea (North Korea) have materially increased the risks of a serious economic or security event on the peninsula,” the report read.
Antique: The rich food preparations in Antique could be the ticket for its inclusion in the country’s food heritage map.
‘Antique has not only an intact ecology, with pristine water and environment, but the food preparation is also rich,’ said National Commission for Culture and the Arts (NCCA) Commissioner Arvin Manuel Villalon on Tuesday.
NCCA chose Antique as the venue for the April 28-30 closing ceremony of the Filipino Food Month, mandated under Proclamation Order 469.
He said hosting the ceremony was already a springboard for the inclusion of the province in the country’s food heritage map.
They learned that Antique has a rich culinary heritage, like the ‘pinindang’ or the unsalted dried fish fry listed in the Ark of Taste.
‘The rice-based desserts like ‘sapal’ or fermented rice and food related to rituals or healing by the indigenous people are also good to be mapped,’ Villalon said.
Antique also needs to label its products for people to know they are from the province., he added.
‘The preserved
food preparations of Antique will be documented in the cultural mapping led by the University of the Philippines in the Visayas (UPV) with the University of Antique and the local government unit as overseer,’ he said.
The cultural mapping that started before the pandemic and will culminate in August this year includes the documentation of the rich food preparations in Antique.
Senator Loren Legarda, in her message read by NCCA Special Projects Unit Head Mark Omaña at the start of the three-day event on April 28, said that ‘the cultivation, preparation, and partaking of food are intricately interwoven with our cultural identity, our traditions, our values, and even our stewardship of nature.’
Legarda, who authors Senate Bill 244 or the proposed Philippine Culinary Heritage Act, hopes to promote Filipino culinary practices in the education system and preserve native ingredients and cooking methods.
